PALISADE BIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
PALISADE BIO, INC. (PALI) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $500.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-22.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2021-03-22
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2020 was $500.00K, a 25.50% decline from fiscal 2019.
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2019 was $671.10K, a 227.37% increase from fiscal 2018.
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2018 was $205.00K, a 32.12% decline from fiscal 2017.
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2017 was $302.00K, a 88.57% decline from fiscal 2016.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|
| 2020-12-31 | $500.00K 10-K · filed 2021-03-22 |
| 2019-12-31 | $671.10K 10-K · filed 2021-03-22 |
| 2018-12-31 | $205.00K 10-K · filed 2020-03-27 |
| 2017-12-31 | $302.00K 10-K · filed 2019-03-22 |
| 2016-12-31 | $2.64M 10-K · filed 2018-04-02 |
| 2015-12-31 | $2.21M 10-K · filed 2017-03-23 |
| 2014-12-31 | $1.81M 10-K · filed 2016-03-14 |
| 2013-12-31 | $1.17M 10-K · filed 2016-03-14 |
| 2012-12-31 | $557.00K 10-K · filed 2015-03-16 |
| 2011-12-31 | $3.10M 10-K · filed 2014-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |